Searchable abstracts of presentations at key conferences in endocrinology
Endocrine Abstracts (2024) 101 PS3-24-01 | DOI: 10.1530/endoabs.101.PS3-24-01

ETA2024 Poster Presentations Translational thyroid cancer research-2 (10 abstracts)

HIF-1α inhibitors could successfully inhibit the progression of differentiated thyroid cancer

Peter Lee 1 , Seung Min Jeong 2 & Jun-O Jin 3


1University of Ulsan College of Medicine, Biochemistry & Molecular Biology, Seoul, Korea, Rep. of South; 2College of Medicine, The Catholic University of Korea, Biochemistry, Korea, Rep. of South; 3University of Ulsan College of Medicine, Korea, Rep. of South


Hypoxia-inducible factor (HIF)-1α plays an important role in cancer progression. In various cancers, including thyroid cancer, overexpression of HIF-1α is related to poor prognosis or treatment response. However, few studies have investigated the role of HIF-1α inhibition in thyroid cancer progression. We evaluated the utility of the HIF-1α inhibitor IDF-11774 in vitro utilizing two thyroid cancer cell lines, K1 and BCPAP. Both cell lines were tested to elucidate the effects of IDF-11774 on cell proliferation and migration using soft agar and invasion assays. Here, we found that a reduction of HIF-1α expression in BCPAP cells was observed after treatment with IDF-11774 in a dose-dependent manner. Moreover, cell proliferation, migration, and anchorage-independent growth were effectively inhibited by IDF-11774 in BCPAP cells but not in K1 cells. Additionally, invasion of BCPAP but not K1 cells was controlled with IDF-11774 in a dose-dependent manner. Our findings suggest that promoting the degradation of HIF-1α could be a strategy to manage progression and that HIF-1α inhibitors are potent drugs for thyroid cancer treatment.

Volume 101

46th Annual Meeting of the European Thyroid Association (ETA) 2024

European Thyroid Association 

Browse other volumes

Article tools

My recent searches

No recent searches.